Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH
Executive Summary
Emerging Company Profile: Belgium’s Promethera presented preclinical data for HepaStem, its liver-derived stem cell candidate for NASH, fibrosis and acute-on-chronic liver disease, at the AASLD meeting. With what appears to be a solid safety profile, the company hopes to move into clinical studies in the near term.
You may also be interested in...
Asian Investors Bankroll €40m Promethera Biosciences Series D
Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
Belgian Life Science Investor Exceeds Expectations With New €125m Fund
Fund+ has beaten its €100m target to raise €125m for life science investment in Europe – making it the largest private biotech fund in Belgium.